Global Erythropoietin-Stimulating Agents Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Erythropoietin-Stimulating Agents Market was valued at $11.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 7.5% CAGR, to an estimated market size of $16.5 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global erythropoietin-stimulating agents (ESA) market includes biopharmaceutical drugs that mimic the hormone erythropoietin to stimulate red blood cell production (erythropoiesis). It primarily covers treatments for anemia associated with chronic kidney disease (CKD), chemotherapy, and HIV, while excluding non-biologic iron supplements and oral HIF-PH inhibitors.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Erythropoietin-Stimulating Agents Market in the period 2025-30:
- The escalating global burden of chronic kidney disease (CKD) remains the primary driver for sustained demand in the ESA market.
- Rapid maturation of the biosimilars sector is significantly lowering acquisition costs and expanding treatment access in price-sensitive regions.
- Increasing cancer prevalence and the adoption of aggressive chemotherapy regimens are driving the growth of the oncology-related anemia segment.
- A market-wide shift toward subcutaneous self-administration is facilitating the transition of care from hospitals to home-care settings.
- Strict regulatory guidelines regarding cardiovascular and thromboembolic risks continue to influence dosing protocols and limit aggressive treatment targets.
- Development of long-acting formulations with extended half-lives is improving patient convenience by reducing the required frequency of injections.
- Expanding healthcare infrastructure and rising diagnosis rates in emerging economies, particularly in Asia, are creating significant new growth opportunities.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Chronic Kidney Disease (CKD)
- Oncology (Chemotherapy-induced Anemia)
- Other Indications (HIV, Surgery, etc.)